NASDAQ:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis $1.62 -0.05 (-2.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.53▼$1.6950-Day Range$1.16▼$2.2252-Week Range$1.03▼$3.67Volume46,249 shsAverage Volume1.17 million shsMarket Capitalization$10.97 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside825.9% Upside$15.00 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.36) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.86 out of 5 starsMedical Sector251st out of 936 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry2nd out of 9 stocks 3.5 Analyst's Opinion Consensus RatingBioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioRestorative Therapies has only been the subject of 1 research reports in the past 90 days.Read more about BioRestorative Therapies' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.62% of the float of BioRestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBioRestorative Therapies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioRestorative Therapies has recently decreased by 46.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 2.6 News and Social Media Coverage News SentimentBioRestorative Therapies has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioRestorative Therapies this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioRestorative Therapies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($2.36) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioRestorative Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About BioRestorative Therapies Stock (NASDAQ:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesJuly 23, 2024 | sg.finance.yahoo.comBioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational MedicineJuly 23, 2024 | globenewswire.comBioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational MedicineJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."June 27, 2024 | globenewswire.comBioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease ProgramJune 17, 2024 | globenewswire.comBioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial ResultsJune 13, 2024 | investorplace.comWhy Is BioRestorative Therapies (BRTX) Stock Up 42% Today?June 13, 2024 | investorplace.comWhy Is BioRestorative Therapeutics (BRTX) Stock Up 42% Today?June 13, 2024 | globenewswire.comBioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease ProgramJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."June 4, 2024 | globenewswire.comBioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare ConferenceMay 25, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance NoticeMay 24, 2024 | globenewswire.comBioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance NoticeMay 17, 2024 | seekingalpha.comBioRestorative Therapies reports Q1 resultsMay 15, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 14, 2024 | globenewswire.comBioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 8, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityMay 8, 2024 | globenewswire.comBioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityApril 30, 2024 | globenewswire.comBioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024See More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/11/2024Today7/27/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+825.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,410,000.00 Net Margins-7,303.33% Pretax Margin-6,310.00% Return on Equity-96.09% Return on Assets-85.36% Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.86 Sales & Book Value Annual Sales$150,000.00 Price / Sales73.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.66Miscellaneous Outstanding Shares6,770,000Free Float5,308,000Market Cap$10.97 million OptionableNot Optionable Beta63.43 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $954.17kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $368.12kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $891.67kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsOntrakNASDAQ:OTRKMangoceuticalsNASDAQ:MGRXMarpaiNASDAQ:MRAIGreenbrook TMSNASDAQ:GBNHFGlobal Cord BloodNYSE:CORBFView All CompetitorsInsiders & InstitutionsStoneX Group Inc.Bought 34,850 shares on 5/1/2024Ownership: 0.515%Francisco SilvaBought 1,708 shares on 4/8/2024Total: $1,981.28 ($1.16/share)Dale BroadrickBought 86,041 shares on 2/9/2024Total: $113,574.12 ($1.32/share)Dale BroadrickBought 36,374 shares on 2/7/2024Total: $50,196.12 ($1.38/share)Dale BroadrickSold 250 sharesTotal: $470.00 ($1.88/share)View All Insider TransactionsView All Institutional Transactions BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed this year? BioRestorative Therapies' stock was trading at $1.7399 at the beginning of the year. Since then, BRTX shares have decreased by 6.9% and is now trading at $1.62. View the best growth stocks for 2024 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (NASDAQ:BRTX) issued its quarterly earnings data on Tuesday, June, 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 96.09% and a negative net margin of 7,303.33%. How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BRTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
